Skip to content

Study · Randomized controlled trial · n = 28 · 2018

6 results

Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX).

Siskind DJ, Russell AW, Russell AW, Gamble C, Winckel K, Mayfield K, Hollingworth S, Hickman I, Siskind V, Kisely S

Diabetes, obesity & metabolism19 Dec 2017Cited by 71 (Europe PMC)

PMID29194917 (opens in a new tab)DOI10.1111/dom.13167 (opens in a new tab)PepBankPUB-29194917
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In clozapine-treated adults with obesity and schizophrenia, more exenatide recipients achieved >5% weight loss than usual-care recipients.

    In plain wordsIn adults receiving clozapine, more patients lost over 5% of their weight with exenatide than usual care.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseMore than 5% weight loss
    Study

    n = 28

    Comparator
    Usual care
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Responders
    6 people
    exenatide
    Responders
    1 people
    usual care

    Source sentences

    Summary
    Six people on exenatide achieved >5% weight loss vs one receiving usual care (P = .029).
    2 context sentences
    Summary · context
    This randomized, controlled, open-label, pilot trial evaluated weekly exenatide for weight loss among clozapine-treated obese adults with schizophrenia, with or without T2DM.
    Summary · context
    A total of 28 outpatients were randomized to once-weekly extended-release subcutaneous exenatide or usual care for 24 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In clozapine-treated adults with obesity and schizophrenia, exenatide reduced weight more than usual care.

    In plain wordsIn adults receiving clozapine, exenatide reduced weight more than usual care.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWeight change
    Study

    n = 28

    Comparator
    Usual care
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Weight change
    −5.29 kg
    exenatide
    Weight change
    −1.12 kg
    usual care

    Source sentences

    Summary
    Compared with usual care, participants on exenatide had greater mean weight loss (-5.29 vs -1.12 kg; P = .015) and body mass index reduction (-1.78 vs -0.39 kg/m2 ; P = .019), and reduced fasting glucose (-0.34 vs 0.39 mmol/L; P = .036) and glycated haemoglobin levels (-0.21% vs 0.03%; P = .004).
    2 context sentences
    Summary · context
    This randomized, controlled, open-label, pilot trial evaluated weekly exenatide for weight loss among clozapine-treated obese adults with schizophrenia, with or without T2DM.
    Summary · context
    A total of 28 outpatients were randomized to once-weekly extended-release subcutaneous exenatide or usual care for 24 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In clozapine-treated adults with obesity and schizophrenia, exenatide reduced BMI more than usual care.

    In plain wordsIn adults receiving clozapine, exenatide reduced body mass index more than usual care.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBMI change
    Study

    n = 28

    Comparator
    Usual care
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    BMI change
    −1.78 kg/m<sup>2</sup>
    exenatide
    BMI change
    −0.39 kg/m<sup>2</sup>
    usual care

    Source sentences

    Summary
    Compared with usual care, participants on exenatide had greater mean weight loss (-5.29 vs -1.12 kg; P = .015) and body mass index reduction (-1.78 vs -0.39 kg/m2 ; P = .019), and reduced fasting glucose (-0.34 vs 0.39 mmol/L; P = .036) and glycated haemoglobin levels (-0.21% vs 0.03%; P = .004).
    2 context sentences
    Summary · context
    This randomized, controlled, open-label, pilot trial evaluated weekly exenatide for weight loss among clozapine-treated obese adults with schizophrenia, with or without T2DM.
    Summary · context
    A total of 28 outpatients were randomized to once-weekly extended-release subcutaneous exenatide or usual care for 24 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In clozapine-treated adults with obesity and schizophrenia, exenatide reduced fasting glucose versus usual care.

    In plain wordsIn adults receiving clozapine, exenatide reduced fasting blood sugar compared with usual care.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFasting glucose change
    Study

    n = 28

    Comparator
    Usual care
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Fasting glucose change
    −0.34 mmol/L
    exenatide group
    Fasting glucose change
    0.39 mmol/L
    usual care group

    Source sentences

    Summary
    Compared with usual care, participants on exenatide had greater mean weight loss (-5.29 vs -1.12 kg; P = .015) and body mass index reduction (-1.78 vs -0.39 kg/m2 ; P = .019), and reduced fasting glucose (-0.34 vs 0.39 mmol/L; P = .036) and glycated haemoglobin levels (-0.21% vs 0.03%; P = .004).
    2 context sentences
    Summary · context
    This randomized, controlled, open-label, pilot trial evaluated weekly exenatide for weight loss among clozapine-treated obese adults with schizophrenia, with or without T2DM.
    Summary · context
    A total of 28 outpatients were randomized to once-weekly extended-release subcutaneous exenatide or usual care for 24 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In clozapine-treated adults with obesity and schizophrenia, exenatide reduced glycated haemoglobin versus usual care.

    In plain wordsIn adults receiving clozapine, exenatide reduced long-term blood sugar compared with usual care.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c change
    Study

    n = 28

    Comparator
    Usual care
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.21%
    exenatide group
    HbA1c change
    0.03%
    usual care group

    Source sentences

    Summary
    Compared with usual care, participants on exenatide had greater mean weight loss (-5.29 vs -1.12 kg; P = .015) and body mass index reduction (-1.78 vs -0.39 kg/m2 ; P = .019), and reduced fasting glucose (-0.34 vs 0.39 mmol/L; P = .036) and glycated haemoglobin levels (-0.21% vs 0.03%; P = .004).
    2 context sentences
    Summary · context
    This randomized, controlled, open-label, pilot trial evaluated weekly exenatide for weight loss among clozapine-treated obese adults with schizophrenia, with or without T2DM.
    Summary · context
    A total of 28 outpatients were randomized to once-weekly extended-release subcutaneous exenatide or usual care for 24 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In clozapine-treated adults with obesity and schizophrenia, other metabolic syndrome components did not differ significantly between exenatide and usual care.

    In plain wordsIn adults receiving clozapine, other metabolic syndrome measures did not differ significantly between exenatide and usual care.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeOther metabolic syndrome components
    Study

    n = 28

    Comparator
    Usual care
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in other metabolic syndrome components.
    2 context sentences
    Summary · context
    This randomized, controlled, open-label, pilot trial evaluated weekly exenatide for weight loss among clozapine-treated obese adults with schizophrenia, with or without T2DM.
    Summary · context
    A total of 28 outpatients were randomized to once-weekly extended-release subcutaneous exenatide or usual care for 24 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.